BRIM Biotechnology receives FDA Orphan Drug Designation for BRM424 to treat neurotrophic keratitis

BRIM Biotechnology, Inc. ("BRIM," TPEx 6885) is pleased to announce that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for BRM424 in the treatment of neurotrophic keratitis.

PHASTAR Joins Oncology Development Programme (ODP2) to Accelerate Development of Novel Cancer Innovations

PHASTAR Joins Oncology Development Programme (ODP2) to Accelerate Development of Novel Cancer Innovations London, UK and Durham, NC – 08 December, 2022 – PHASTAR, a global specialist biometrics contract research organization (CRO), has joined Lean Life Science’s Oncology Development Programme (ODP2). The targeted programme aims to identify and accelerate novel oncology innovations into commercially-attractive assets by offering support to academics and early-stage companies.

Verana Health and the American Academy of Ophthalmology Launch the Verana Research Network, an IRIS Registry Initiative

Partnership seeks to increase clinical trials access, accelerate recruitment, and advance ophthalmic research

PHASTAR Launches Pro-Bono Scheme for Charities

PHASTAR, a global specialist biometrics contract research organization (CRO), has announced the launch of a pro-bono scheme to give charities access to its volunteer statisticians, data scientists, data managers and programmers at no cost.

Cinchy Scores 5/5 For Product Vision Criterion In Major Enterprise Data Fabric Report

Cinchy was rated ‘best product vision’ in the Forrester Wave for Enterprise Data Fabric, receiving the highest score in that category. The company is on a mission to simplify the way the world works with data. It streamlines the way data’s managed, accessed and used by organizations, and enables them to regain control while collaborating securely in real-time through a single network of interconnected data. It pioneers dataware, a new technology category that can be thought of as the next tech revolution following hardware and software. This essentially frees data from applications – a major advance and breakaway from a 40-year technology norm that required data to be integrated with each new application a company builds, taking up to half of entire IT budgets. See more in the announcement: https://cinchy.com/news/cinchy-scores-5/5-for-product-vision-criterion-in-major-enterprise-data-fabric-report and please let me know if I can provide anything further. Thanks, Amanda Schweitzer amanda@cdc.agency (845) 453-0026

Recipharm announces extension of commercial manufacturing to support RedHill Biopharma’s Talicia® to 2026

Global contract development and manufacturing organization (CDMO) Recipharm, today announced an extension of the ongoing commercial manufacturing of RedHill Biopharma’s (Nasdaq: RDHL) drug, Talicia® for the treatment of H. pylori infection, to 2026.

Pharma and healthcare leaders discuss the innovations to fix our health system at Pharma Integrates 2022

With the UK’s health system under pressure, leaders and innovators from across pharma and healthcare gathered at London Tower Bridge to discuss the future of the sector at the 11th annual Pharma Integrates event.

Ohio Gastroenterology Adds Digital Pre- and Post-care Engagement Tools Through Orbita Platform

MultiOmic Health forges research collaboration with Northern Care Alliance NHS Foundation Trust in diabetic kidney disease

MultiOmic Health, an artificial intelligence-enabled precision medicine discovery company, today announces the signing of a research collaboration agreement with Northern Care Alliance (NCA) NHS Foundation Trust in Manchester, England.

LogicStream Health and FDB Collaborate to Help Improve Management of Drug Shortages

LogicStream Health and FDB Collaborate to Help Improve Management of Drug Shortages . LogicStream’s Drug Supply App™ now recommends therapeutic alternatives to minimize impact of drug supply disruptions

Lonza’s API Mid-Scale Manufacturing Facility Expansion in Nansha Enters Commercial Operation

BRIM Biotechnology, Inc. raises $20 million in Series E funding round

BRIM Biotechnology, Inc. ("BRIM," TPEx 6885), a clinical-stage biotechnology company advancing novel regenerative therapies to help combat and cure ophthalmology and degenerative joint diseases, announced today that it has raised $20 million in its Series E funding round. This demonstrates the heightened interest and growing demand for new treatments for Dry Eye Disease (DED).

MIB Agents Awards $100,000 Grant for Pediatric Osteosarcoma Research at MD Anderson

MIB Agents, a leading pediatric osteosarcoma nonprofit dedicated to Making It Better for its community of patients, caregivers, doctors, and researchers, has awarded a $100,000 research grant to Andy Livingston, M.D., a clinician and researcher in Sarcoma Medical Oncology and in Pediatric Oncology at The University of Texas MD Anderson Cancer Center. Ann Graham, Founder and Executive Director of MIB Agents, and Christina Ip-Toma, MIB Agents’ Director of Scientific Programs, presented the award to Dr. Livingston on Dec. 1 in Houston.

AES Clean Technology launches OMNI™ Electric Utility Raceway

This latest product is an innovative power and data management system that reduces risk and accelerates cleanroom delivery for the life sciences and pharmaceutical industry.

REFERENCE MATERIALS FOR CALIBRATION VERIFICATION TESTING OF CHOLESTEROL ASSAYS NOW AVAILABLE FROM VERICHEM

Emplicure AB and Quotient Sciences Announce an Integrated Manufacturing and Clinical Testing Partnership for Emplicure’s First Clinical Pharmacokinetic Study for EMPLI03

Quotient Sciences, a global drug development and manufacturing accelerator, today announced a partnership with Emplicure, a Swedish pharmaceutical company focused on chronic pain and abuse-deterrent formulations.

Foundational partnership with Paradigm4 enables Alnylam Pharmaceuticals to rapidly accelerate RNAi- based drug target discovery

The Mobile Health/Central Lab Interface, an opportunity for DCT efficiency

The Mobile Health/Central Lab Interface, an opportunity for DCT efficiency How streamlining relations between central labs and mobile health providers can get the most from hybrid and decentralised clinical trials

Upgrading to FFP3 face masks in hospitals could save the NHS £360m a year and help slash patient waiting lists

The NHS could save up to £360M per year by using FFP3 face masks – the NHS already has a large stockpile of these masks so there is no current need to purchase more. Independent studies commissioned by PPE manufacturer Globus Group and carried out by York Economic Health Consortium and Vital Economics confirm that these masks may be better at preventing respiratory infection and resulting staff days off.

CD ComputaBio Introduces PyMOL Software for Bioinformatics Analysis